Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. - Wikidata - awgldk - TriplyDB

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma.

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma.

http://www.wikidata.org/entity/Q37236041

about

The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation Hodgkin's lymphoma in adults: diagnosis, treatment and follow-up.Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma.Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.Role of hematopoietic stem cell transplantation in relapsed/refractory hodgkin lymphoma Relapsed Hodgkin lymphoma: management strategies Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response".Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma.Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.Allogeneic transplantation for Hodgkin's lymphoma.The role of autologous transplantation in Hodgkin lymphoma.Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma.FDG PET/CT in children and adolescents with lymphoma.Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma.High-dose therapy followed by stem cell transplantation in Hodgkin's lymphoma: past and future.Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!Current status of prognostication in classical Hodgkin lymphoma.Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma.Feasibility of cell therapy in multiple sclerosis: a systematic review of 83 studies.Current role of FDG PET/CT in lymphoma.Update on salvage options in relapsed/refractory hodgkin lymphoma after autotransplant.Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents.Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era.The GHSG Approach to Treating Hodgkin's Lymphoma.Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.Evolution of lymphoma staging and response evaluation: current limitations and future directions.

P2860

Q26822480-3D7D963D-9AED-42E3-8B6B-497BB0C5FEA2 Q27022992-2DEDDE9C-741B-4680-9927-574E947D449B Q33400803-885EDF96-884C-4D33-AFB8-58AEBE91B8D8 Q33406827-8526F627-0F2B-4250-B596-CD02F852F048 Q33828956-7F2494EA-A326-45F8-A7B2-379F38855C35 Q33886267-0E1C27F7-C81E-4386-AAEC-C655388C35A2 Q34664223-1DF7133C-304F-4AE3-AF89-4D4195162D82 Q35038852-5F541079-9C7C-438D-8B00-19A764F4CB4D Q35194592-B004B4F4-4D39-4599-AC58-841499584BF5 Q35196478-AE048EFC-F9C0-4DA1-86F0-2F7E69BCB55A Q35705317-482049D0-DF92-4945-8F29-82DBDDACD0B3 Q35930635-DB356813-D869-44B7-9A85-34A6B262AF92 Q36094726-1B2BE661-F437-4B85-ADBB-E3D67CE34F13 Q36248964-99280F67-0D1F-425E-99F8-7D9AC28282C6 Q36371623-FB9257B1-8A54-4D57-98D8-C4DFE03912DF Q36404763-0B9169BE-D921-47B3-9BC9-3B8151B023D3 Q37008427-8D338C90-02AF-44DF-8255-25151E9F587B Q37126593-14887DB5-334B-4CD3-ACA7-5D30EA3BC2CE Q37144956-F8527C12-F00D-47F2-9B84-FD48B092BD9A Q37216194-52776647-2C9F-4761-8390-3AF36EEFA2F7 Q37221563-7ED6C1FB-D371-437F-9FD9-C6097BFE74A2 Q37240835-E5E728AC-BB3D-492F-9BBF-0DDFC859B000 Q37820685-2649EAD7-B263-461C-BA0A-715BA5A408E8 Q37874982-3DBB81CF-65F8-45B3-8548-6794514B2D82 Q37934952-F47D3644-0285-4181-A53A-C26EB791EB96 Q38092706-A7748B96-290F-4725-BEA2-852354B6CA46 Q38099028-0A39A904-A5F2-4466-A451-6A86FA0C3953 Q38132819-9F10082D-4125-4190-AF9E-97EA866D5840 Q38179975-1F60C927-BD65-4467-8C3D-E683FA6BCB86 Q38185063-9B398885-9C6A-4927-9427-201F01F402E5 Q38185983-36F1B46F-9280-4968-A361-DA2BDA127C1A Q38186029-2C03CCE0-8BCD-43DD-ABD1-CE22A9D26FC6 Q38187365-2AF20334-01E6-44D8-BAAA-436B08857CEF Q38227567-BAA0F9F7-E469-460D-81DA-3362F5342877 Q38264356-3592089C-7B4B-4CB6-88A9-BDEBD2A32E9D Q38361620-3CB44AC2-7481-4443-9E4D-83BCFF9A59DE Q38506223-A8872BB7-6E78-412D-BD54-2F32777C98C3 Q38600671-88C74151-C711-4B62-9C0B-E5F865DE79E9 Q38664909-DD60F8D5-B793-4EB5-A00A-1E9EC1B0CBD1 Q38671671-CEA420E7-A8E5-4ABC-8C81-08AECC338A83

P2860

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma.

http://www.wikidata.org/entity/Q37236041

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 August 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pretransplantation functional ...... d refractory Hodgkin lymphoma.

@en

Pretransplantation functional ...... d refractory Hodgkin lymphoma.

@nl

type

label

Pretransplantation functional ...... d refractory Hodgkin lymphoma.

@en

Pretransplantation functional ...... d refractory Hodgkin lymphoma.

@nl

prefLabel

Pretransplantation functional ...... d refractory Hodgkin lymphoma.

@en

Pretransplantation functional ...... d refractory Hodgkin lymphoma.

@nl

P1433

Q37236041-3E5AAA6B-0330-4B8E-98A3-E589C82AB127

P1476

Q37236041-CB4DFB73-3B77-4044-B839-F6AB13011CC8

P2093

Q37236041-3E1BCF74-5A0C-4C0D-B21C-DF357042EA3B

Q37236041-7CE1DFB6-D5DF-44C9-8B53-CD33B6DADE25

Q37236041-83774DE2-79ED-4BD8-8924-4951D1DA5DF7

Q37236041-A22F73EE-4498-467E-8F5E-4E6EDFDD4CEE

Q37236041-A7AB9EFD-C13B-4814-B9AC-255E964D9A4F

Q37236041-EC70DA20-F128-48E6-B408-37DB32AFC1AC

P2860

Q37236041-32DB4BAC-B1E9-4105-8A6F-743D1D11D8A2

Q37236041-45E2A6AE-C04E-419B-943A-54CC37BAD6F2

Q37236041-4DE28E51-C92F-44B9-BC76-87826A9467AA

Q37236041-728E4894-ADEF-4A91-B917-D0BE0A7BCC39

Q37236041-82631812-AA04-4CFA-913B-D733F250E2D1

Q37236041-8DAA6AAC-E23B-4C5A-A1DC-CAB49FD34EE0

Q37236041-AD467140-6848-49EA-AD57-1ADAF2C3A172

Q37236041-B2ACF39C-E3D9-4374-920B-2D5DBAFE5E27

Q37236041-C450662F-2812-48AA-B50A-7B925A018F7C

Q37236041-C79921C2-B060-49C3-9A16-81A683F841C8

P304

Q37236041-CF139DA8-1EFE-4283-BF94-B328106FB80B

P31

Q37236041-9835ABF6-4F19-4120-9C21-A9B5E454015E

P356

Q37236041-213309F4-76DC-44DC-8220-9B2EEBF8C4E3

P407

Q37236041-7C4E8A25-5A7C-48FD-8B6C-8B8E74FCC14B

P433

Q37236041-C379CE90-1386-4899-B960-B66358B6D78D

P478

Q37236041-38D19E5E-7FCB-44CC-A195-A2DA6E171F3A

P50

Q37236041-4054B2ED-2FBF-4D2F-873A-0594C1C4A22D

P577

Q37236041-1537A940-4CAA-4424-8593-398EAA9E4C5B

P5875

Q37236041-FD6744F9-CD18-4A87-88C2-36DE3CC3249A

P698

Q37236041-375818F5-149E-4336-B338-9B6D1D220A5F

P932

Q37236041-9DF421C4-7FBD-49ED-B17D-5B02CF5C87E1

P356

BLOOD-2010-05-282756

P1433

P1476

Pretransplantation functional ...... d refractory Hodgkin lymphoma.

@en

P2093

Alison J Moskowitz

http://www.w3.org/2001/XMLSchema#string

Craig H Moskowitz

http://www.w3.org/2001/XMLSchema#string

Jill M Vanak

http://www.w3.org/2001/XMLSchema#string

Joachim Yahalom

http://www.w3.org/2001/XMLSchema#string

Jocelyn C Maragulia

http://www.w3.org/2001/XMLSchema#string

Tarun Kewalramani

http://www.w3.org/2001/XMLSchema#string

P2860

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.

High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging.

Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.

Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation.

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation.

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

P304

4934-4937

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-05-282756

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P50

Andrew D Zelenetz

P577

2010-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45821248

http://www.w3.org/2001/XMLSchema#string

P698

20733154

http://www.w3.org/2001/XMLSchema#string

P932

3799204

http://www.w3.org/2001/XMLSchema#string